Results 1 to 10 of about 124,982 (193)

The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants [PDF]

open access: yesClinical and Translational Science
Previous pharmacogenetic findings for beta‐blocker pharmacodynamic candidate genes (ADRB1, ADRB2, ADRA2C, GRK4, and GRK5) have been inconsistent. Therefore, the purpose of this study was to determine whether interactions of pharmacodynamic variants with ...
Jasmine A. Luzum   +5 more
doaj   +2 more sources

Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib [PDF]

open access: yesMedicina
Background and Objectives: Erlotinib, a tyrosine kinase inhibitor (TKI), is an established therapy for patients with metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.
Oğuzhan Yıldız   +9 more
doaj   +2 more sources

Persistent Beta‐Blocker Therapy Reduces Long‐Term Mortality in Patients With Acute Ischemic Stroke With Elevated Heart Rates [PDF]

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Elevated heart rate in patients with acute ischemic stroke is associated with increased risk of mortality. Beta‐blocker therapy is well known to reduce heart rate.
Keon‐Joo Lee   +35 more
doaj   +2 more sources

Atenolol versus losartan in children and young adults with Marfan's syndrome [PDF]

open access: yes, 2014
BACKGROUND : Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers.
Atz, A.M.   +33 more
core   +17 more sources

Lower In‐Hospital Mortality With Beta‐Blocker Use at Admission in Patients With Acute Decompensated Heart Failure

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background It remains unclear whether beta‐blocker use at hospital admission is associated with better in‐hospital outcomes in patients with acute decompensated heart failure.
Yodo Tamaki   +22 more
doaj   +1 more source

The Association of Beta-Blocker Use and Bone Mineral Density Level in Hemodialysis Patients: A Cross-Sectional Study

open access: yesMedicina, 2023
Background and Objectives: Osteoporosis results in increasing morbidity and mortality in hemodialysis patients. The medication for treatment has been limited.
Suthiya Anumas   +4 more
doaj   +1 more source

A Clinical-Epidemiological Study on Beta-Blocker Poisonings Based on the Type of Drug Overdose

open access: yesJournal of Toxicology, 2023
Background. Beta‐blockers carry a high risk of potentially causing fatal poisoning if overdosed. We aimed to assess the clinical and epidemiological characteristics of patients with beta-blocker poisoning. Methods.
Nastaran Eizadi-Mood   +4 more
doaj   +1 more source

Beta-blockers for hypertension [PDF]

open access: yesCochrane Database of Systematic Reviews, 2017
Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line
Wiysonge, Charles S.   +4 more
openaire   +3 more sources

Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study

open access: yesSwiss Medical Weekly, 2020
BACKGROUND The European Society of Cardiology recommends beta-blocker prescription after ST-segment elevation myocardial infarction (STEMI).
Christel Bruggmann   +5 more
doaj   +1 more source

Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease

open access: yesESC Heart Failure, 2021
Aims The number of patients with both chronic obstructive pulmonary disease (COPD) and heart failure (HF) is increasing in Asia, and these conditions often coexist.
Yoshiaki Kubota   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy